These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32343477)

  • 1. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update.
    Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
    Hepatol Res; 2020 Jul; 50(7):791-816. PubMed ID: 32343477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis.
    Asahina Y;
    Hepatol Res; 2020 Jul; 50(7):775-790. PubMed ID: 32298527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update.
    Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
    Hepatol Res; 2020 Aug; 50(8):892-923. PubMed ID: 32343469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [JSH guidelines for the management of hepatitis C virus infection (version 3)].
    Tanaka A
    Nihon Rinsho; 2015 Feb; 73(2):221-7. PubMed ID: 25764674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
    Kudo M; Kawamura Y; Hasegawa K; Tateishi R; Kariyama K; Shiina S; Toyoda H; Imai Y; Hiraoka A; Ikeda M; Izumi N; Moriguchi M; Ogasawara S; Minami Y; Ueshima K; Murakami T; Miyayama S; Nakashima O; Yano H; Sakamoto M; Hatano E; Shimada M; Kokudo N; Mochida S; Takehara T
    Liver Cancer; 2021 Jun; 10(3):181-223. PubMed ID: 34239808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    Yoshiji H; Nagoshi S; Akahane T; Asaoka Y; Ueno Y; Ogawa K; Kawaguchi T; Kurosaki M; Sakaida I; Shimizu M; Taniai M; Terai S; Nishikawa H; Hiasa Y; Hidaka H; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Jul; 56(7):593-619. PubMed ID: 34231046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Sucher AJ; Hemstreet BA
    Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based clinical practice guidelines for liver cirrhosis 2020.
    Yoshiji H; Nagoshi S; Akahane T; Asaoka Y; Ueno Y; Ogawa K; Kawaguchi T; Kurosaki M; Sakaida I; Shimizu M; Taniai M; Terai S; Nishikawa H; Hiasa Y; Hidaka H; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    Hepatol Res; 2021 Jul; 51(7):725-749. PubMed ID: 34228859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
    Weisberg IS; Jacobson IM
    Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
    Miller MM
    Am J Health Syst Pharm; 2017 Jul; 74(14):1045-1052. PubMed ID: 28687550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.
    Kokudo N; Takemura N; Hasegawa K; Takayama T; Kubo S; Shimada M; Nagano H; Hatano E; Izumi N; Kaneko S; Kudo M; Iijima H; Genda T; Tateishi R; Torimura T; Igaki H; Kobayashi S; Sakurai H; Murakami T; Watadani T; Matsuyama Y
    Hepatol Res; 2019 Oct; 49(10):1109-1113. PubMed ID: 31336394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
    Huang Y; Li MH; Hou M; Xie Y
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).
    Kokudo N; Hasegawa K; Akahane M; Igaki H; Izumi N; Ichida T; Uemoto S; Kaneko S; Kawasaki S; Ku Y; Kudo M; Kubo S; Takayama T; Tateishi R; Fukuda T; Matsui O; Matsuyama Y; Murakami T; Arii S; Okazaki M; Makuuchi M
    Hepatol Res; 2015 Jan; 45(2):. PubMed ID: 25625806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.